If you’ve ever wanted to own a piece of the vision care industry, that time may be coming soon: Bausch + Lomb Corporation has publicly filed a Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering (IPO). The company has filed with the appropriate authorities in both the United States, as well in the provinces and territories of Canada (other than Quebec).
This comes on the heels of a previous announcement, which shared the company’s intentions of Bausch Health Companies Inc. to separate its eye health business into a wholly owned subsidiary: Bausch + Lomb Corporation.
As of now, the number of common shares offered, along with the price range for the IPO, have not been divulged. Copies of the prospectus and the preliminary base PREP prospectus, when available, may be obtained by mail or phone, as well as email at prospectus-ny@ny.email.gs.com.
Of course, the IPO isn’t set in stone and is subject to market conditions. In any case, this is a big announcement for the industry … and for those keen to invest in it.
